Keros Therapeutics, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$338M
↓-45.1% -$278Mvs FY2024
Total Liabilities
$35M
↓-21.3% -$9Mvs FY2024
Equity
$303M
↓-47.0% -$268Mvs FY2024
Cash
$287M
↓-48.7% -$273Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $338M | $616M |
| Current Assets | $315M | $589M |
| Cash | $287M | $560M |
| ST Investments | $0 | $0 |
| Receivables | $4M | $3M |
| Inventory | $0 | $0 |
| Other Current | $24M | $26M |
| Non-Current Assets | $23M | $27M |
| PPE | $4M | $4M |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $18M | $23M |
| Total Liab+Eq | $338M | $616M |
| Current Liab. | $20M | $27M |
| Accounts Payable | $2M | $5M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $18M | $23M |
| Non-Current Liab. | $14M | $17M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $14M | $17M |
| Equity | $303M | $572M |
| Retained Earnings | $482M | $569M |
| Other Equity | $0 | $3M |
QuarterCharts · SEC EDGAR data · KROS · Comparing FY2025 vs FY2024